(Q33383571)

26 July 2017

title

Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma (English)

1 reference

26 July 2017

1 reference

Pierluigi Porcu

10

0 references

Mehdi Hamadani

object named as

Mehdi Hamadani

2

0 references

John C. Byrd

12

object named as

John C Byrd

1 reference

26 July 2017

1

Kristie A Blum

1 reference

26 July 2017

8

Robert Baiocchi

1 reference

26 July 2017

11

Steven M Devine

1 reference

26 July 2017

4

Gerard Lozanski

1 reference

26 July 2017

9

Thomas S Lin

1 reference

26 July 2017

3

Gary S Phillips

1 reference

26 July 2017

Amy J Johnson

5

1 reference

26 July 2017

David M Lucas

6

1 reference

26 July 2017

Lisa L Smith

7

1 reference

26 July 2017

publication date

1 March 2009

1 reference

26 July 2017

1 reference

26 July 2017

volume

50

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

349-356

1 reference

Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3695225

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3695225

Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3695225

Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3695225

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3695225

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3695225

Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3695225

Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3695225

Neurotoxicity of purine analogs: a review

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3695225

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3695225

Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3695225

Optimal two-stage designs for phase II clinical trials

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3695225

Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3695225

Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3695225

Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3695225

Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3695225

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

14 July 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902730227

Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902730227

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902730227

Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902730227

Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902730227

Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902730227

Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902730227

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902730227

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902730227

Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902730227

Addition of cladribine to induction/consolidation regimen does not impair peripheral blood stem cell mobilization and bone marrow harvest for autotransplantation in acute myeloid leukemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902730227

Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma

21 January 2018

1 reference

12 December 2020

ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study

1 reference

12 December 2020

Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia

1 reference

12 December 2020

Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment

1 reference

12 December 2020

The activity and toxicity of low dose clofarabine against relapsed or refractory myeloma

1 reference

12 December 2020

Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non Hodgkin lymphoma patients

1 reference

12 December 2020

10.1080/10428190902730227

Identifiers

DOI

1 reference

26 July 2017

1 reference

26 July 2017

1 reference